Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology

Table 1 Tau reductions in 20-month-old female 3xTg-AD mice following Aβ42 immunotherapy

Non-soluble fraction						Detergent soluble fraction
	DNA Aβ42 vaccine Comparison to control mice		Aβ42 pep vaccine Comparison to control mice		Comparison DNA and peptide vaccine	DNA Aβ42 vaccine Comparison to control mice		Aβ42 pep vaccine Comparison to control mice		Comparison DNA and peptide vaccine
	% tau reduction	p value	% tau reduction	p value	p value	% tau reduction	p value	% tau reduction	p value	p value
Total tau human	- 49%	0.0087**	- 7%	0.8446	0.0418*	- 25%	0.1285	- 3%	0.9754	0.2523
pT231 (AT180)	- 37%	0.0008***	no reduction	0.8291	0.0164*	- 33%	0.0016**	- 19%	0.4767	0.1142
pS396 (PHF)	- 44%	0.0001***	- 7%	0.4312	0.0059**	- 39%	0.0097**	- 12%	0.8775	0.0311*
pT181 (AT270)	- 51%	0.0008***	- 11%	0.5123	0.0115*	- 49%	0.0005***	- 20%	0.3686	0.0712
pS199	- 42%	< 0.0001****	− 13%	0.2496	0.0164*	- 40%	0.0002***	- 5%	0.5995	0.0115*

Bold letters indicate differences higher than 20% in DNA Aβ42 trimer immunized mice compared to Aβ42 peptide immunized mice; letters in bold cursive font indicate high significance for differences in reduction of tau in DNA Aβ42 trimer and Aβ42 peptide immunized mice compared to the control mice, and in the comparison of the two immunization groups (Mann Whitney u test).
* indicates p values ≤0.05, ** indicates p values ≤0.005, *** indicates p values ≤0.001, and **** indicates p values < 0.0001. All data are based on the analyses and comparison of seven DNA Aβ42 trimer immunized mice, nine Aβ42 peptide immunized mice, and 14 age and gender matched 3xTg-AD control mice

ISSN: 1758-9193